key: cord-1043164-fgzrhs2i
authors: Brouwer, Philip J.M.; Caniels, Tom G.; van der Straten, Karlijn; Snitselaar, Jonne L.; Aldon, Yoann; Bangaru, Sandhya; Torres, Jonathan L.; Okba, Nisreen M.A.; Claireaux, Mathieu; Kerster, Gius; Bentlage, Arthur E.H.; van Haaren, Marlies M.; Guerra, Denise; Burger, Judith A.; Schermer, Edith E.; Verheul, Kirsten D.; van der Velde, Niels; van der Kooi, Alex; van Schooten, Jelle; van Breemen, Mariëlle J.; Bijl, Tom P. L.; Sliepen, Kwinten; Aartse, Aafke; Derking, Ronald; Bontjer, Ilja; Kootstra, Neeltje A.; Wiersinga, W. Joost; Vidarsson, Gestur; Haagmans, Bart L.; Ward, Andrew B.; de Bree, Godelieve J.; Sanders, Rogier W.; van Gils, Marit J.
title: Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
date: 2020-05-12
journal: bioRxiv
DOI: 10.1101/2020.05.12.088716
sha: bc0f6e3003b7457a08d542a7cc8e959b96dad2c6
doc_id: 1043164
cord_uid: fgzrhs2i

The rapid spread of SARS-CoV-2 has a significant impact on global health, travel and economy. Therefore, preventative and therapeutic measures are urgently needed. Here, we isolated neutralizing antibodies from convalescent COVID-19 patients using a SARS-CoV-2 stabilized prefusion spike protein. Several of these antibodies were able to potently inhibit live SARS-CoV-2 infection at concentrations as low as 0.007 µg/mL, making them the most potent human SARS-CoV-2 antibodies described to date. Mapping studies revealed that the SARS-CoV-2 spike protein contained multiple distinct antigenic sites, including several receptor-binding domain (RBD) epitopes as well as previously undefined non-RBD epitopes. In addition to providing guidance for vaccine design, these mAbs are promising candidates for treatment and prevention of COVID-19.

However, severe cases can present with bilateral pneumonia which may rapidly deteriorate into acute respiratory distress syndrome (2) . With such a high number of people being infected worldwide and no proven curative treatment available, health care systems are under severe pressure. Safe and effective treatment and prevention measures for COVID-19 are therefore urgently needed.

During the outbreak of SARS-CoV and Middle Eastern respiratory syndrome coronavirus (MERS-CoV), plasma of recovered patients containing neutralizing antibodies (NAbs) was used as a safe and effective treatment option to decrease viral load and reduce mortality in severe cases (3, 4) . Recently, a small number of COVID-19 patients treated with convalescent plasma, showed clinical improvement and a decrease in viral load within the following days (5) . An alternative treatment strategy is offered by administering purified monoclonal antibodies (mAbs) with neutralizing capacity. mAbs can be thoroughly characterized in vitro and easily expressed in large quantities. In addition, due to the ability to control dosing and composition, mAb therapy improves the efficacy over convalescent plasma treatment and prevents the potential risks of antibody-dependent enhancement (ADE) from non-or poorly NAbs present in plasma which consists of a polyclonal mixture (6) . Recent studies with patients infected with the Ebola virus highlight the superiority of mAb treatment over convalescent plasma treatment (7, 8) . Moreover, mAb therapy has been proven safe and effective against influenza virus, rabies virus, and respiratory syncytial virus (RSV) (9) (10) (11) .

The main target for NAbs on coronaviruses is the spike (S) protein, a homotrimeric glycoprotein that is anchored in the viral membrane. Recent studies have shown that the S protein of SARS-CoV-2 bears considerable structural homology to SARS-CoV, with the S protein consisting of two subdomains: the N-terminal S1 domain, which contains the receptorbinding domain (RBD) for the host cell receptor angiotensin converting enzyme-2 (ACE2) and the S2 domain, which contains the fusion peptide (12, 13) . Similar to other viruses containing class-1 fusion proteins (e.g. HIV-1, RSV and Lassa virus), the S protein undergoes a conformational change upon host cell receptor binding from a prefusion to postfusion state, enabling merging of viral and target cell membranes (14, 15) . When expressed as recombinant soluble proteins, class-1 fusion proteins generally have the propensity to switch to a postfusion state. However, most NAb epitopes are presented on the prefusion conformation (16) (17) (18) . The recent successes of isolating potent NAbs against HIV-1 and RSV using stabilized prefusion glycoproteins reflect the importance of using the prefusion conformation for isolation and mapping of mAbs against SARS-CoV-2 (19, 20) .

So far, the number of identified mAbs that neutralize SARS-CoV-2 has been limited. Early efforts in obtaining NAbs focused on re-evaluating SARS-CoV-specific mAbs isolated after the 2003 outbreak, that might cross-neutralize SARS-CoV-2 (21, 22) . Although two mAbs were described to cross-neutralize SARS-CoV-2, the majority of SARS-CoV NAbs did not bind SARS-CoV-2 S protein or neutralize SARS-CoV-2 virus (12, (21) (22) (23) . More recently, the focus has shifted from cross-neutralizing SARS-CoV NAbs to the isolation of novel SARS-CoV-2

NAbs from recovered COVID-19 patients (24, 25) . S protein fragments containing the RBD have yielded multiple RBD-targeting NAbs that can neutralize SARS-CoV-2 (24, 25) . In light of the rapid emergence of escape mutants in the RBD of SARS-CoV and MERS, monoclonal NAbs targeting other epitopes than the RBD are a welcome component of any therapeutic antibody cocktail (26, 27) . Indeed, therapeutic antibody cocktails with a variety of specificities have been used successfully against Ebola virus disease (7) and are being tested widely in clinical trials for HIV-1 (28) . NAbs targeting non-RBD epitopes have been identified for SARS-CoV and MERS, supporting the rationale to sort mAbs using the entire ectodomain of the SARS-CoV-2 S protein (29) . In addition, considering the high sequence homology between the S2 subdomain of SARS-CoV-2 and SARS-CoV, using the complete S protein ectodomain instead of only the RBD may allow the isolation of mAbs that cross-neutralize different βcoronaviruses (30) . In an attempt to obtain mAbs that target both RBD and non-RBD epitopes, we set out to isolate mAbs using the complete prefusion S protein ectodomain of SARS-CoV-2.

We collected cross-sectional blood samples from three PCR-confirmed SARS-CoV-2-infected individuals (COSCA1-3) approximately four weeks after symptom onset. COSCA1 (47-yearold male) and COSCA2 (44- year-old female) showed symptoms of an upper respiratory tract infection and mild pneumonia, respectively (Table 1) . Both remained in home-isolation during the course of COVID-19 symptoms. COSCA3, a 69-year-old male, developed a severe pneumonia and became respiratory-insufficient one and a half weeks after symptom onset, requiring admission to the intensive care unit for mechanical ventilation. To identify S proteinspecific antibodies in serum, we generated soluble prefusion-stabilized S proteins of SARS-CoV-2 using stabilization strategies as previously described for S proteins of SARS-CoV-2 and other β-coronaviruses ( Fig. 1A ) (12, 31) . As demonstrated by the size-exclusion chromatography (SEC) trace, SDS-and blue-native PAGE, the resulting trimeric SARS-CoV-2 S proteins were of high purity ( 1C ). In addition, all sera showed cross-reactivity to the S protein of SARS-CoV and neutralized SARS-CoV pseudovirus, albeit with lower potency (Fig. S1 , C and D). The potent S proteinspecific binding and neutralizing responses observed for COSCA3 are in line with earlier findings that severe disease is associated with a strong humoral response (32) . These strong serum binding and neutralization titers prompted subsequent sorting of SARS-CoV-2 S protein-specific B cells for mAb isolation from COSCA1-3.

Peripheral blood mononuclear cells (PBMCs) were stained with dually fluorescently labelled prefusion SARS-CoV-2 S proteins and analyzed for the frequency and phenotype of specific B cells by flow cytometry (Fig. 2A, fig S2) . The analysis revealed a high frequency of S proteinspecific B cells (S-AF647 + , S-BV421 + ) among the total pool of B cells (CD19 + Via-CD3 -CD14 -CD16 -), ranging from 0.68-1.74% (Fig. 2B) . These SARS-CoV-2 S-specific B cells showed a predominant memory (CD20 + CD27 + ) and plasmablasts/plasma cell (PB/PC) (CD20 -CD27 + CD38 + ) phenotype with an average 3-fold significant enrichment of specific B cells in the PB/PC compartment (Fig. 2C) . COSCA3, who experienced severe symptoms, showed the highest frequency of PB/PC in both total (34%) and specific (60%) B-cell compartments (Fig.   2C, fig. S2 ). As expected, the SARS-CoV-2 S protein-specific B cells were enriched in the IgG + and IgM -/IgG -(most likely representing IgA + ) B cell populations, although a substantial portion of the specific B cells were IgM + , particularly for COSCA3 (Fig. 2D ).

SARS-CoV-2 S-specific B cells were subsequently single cell sorted for mAb isolation. In total, 409 paired heavy chain (HC) and light chain (LC) were obtained from the sorted B cells of the three patients (137, 165, and 107 from COSCA1-3, respectively), of which 323 were unique clonotypes. Clonal expansion occurred in all three patients (Fig. 3A) , but was strongest in COSCA3 where it was dominated by HC variable (VH) regions VH3-7 and VH4-39 (34% and 32% of SARS-CoV-2 S-specific sequences, respectively). Even though substantial clonal expansion occurred in COSCA3, the median somatic hypermutation (SHM) was 1.4%, with similar SHM in COSCA1 and COSCA2 (2.1% and 1.4%) (Fig. 3B ). These SHM levels are similar to those observed in response to infection with other respiratory viruses (33) .

A hallmark of antibody diversity is the heavy chain complementarity determining region 3 (CDRH3). Since the CDRH3 is composed of V, D and J gene segments, it is the most variable region of an antibody in terms of both amino acid composition and length. The average length of CDRH3 in the naive human repertoire is 15 amino acids (34), but for a subset of influenza virus and HIV-1 broadly neutralizing antibodies, long CDRH3 regions of 20-35 amino acids are crucial for high affinity antigen-antibody interactions (35, 36) . Even though the mean CDRH3 length of isolated SARS-CoV-2 S protein-specific B cells did not differ substantially from that of a naive population (34), we observed a significant difference in the distribution of CDRH3 length (two sample Kolmogorov-Smirnov test, p = 0.006) (Fig. 3C ). This difference in CDRH3 distribution can largely be attributed to an enrichment of longer (~20 amino acid)

CDRH3s, leading to a bimodal distribution as opposed to a bell-shaped distribution that was observed in the naive repertoire ( Fig. 3C and fig. S3 ).

Next, to determine SARS-CoV-2-specific signatures in B cell receptor (BCR) repertoire usage, we compared Immunogenetics (IMGT)-assigned unique germline V regions from the sorted SARS-CoV-2 S-specific B cells to the well-defined extensive germline repertoire mentioned above ( Fig. 3D ) (34) . In particular VH1-69 and VH3-33 were strongly enriched in COSCA1-3 patients compared to the naive repertoire (by 41 and 14-fold, respectively; Fig. 3D ). The enrichment of VH1-69 has been shown in response to a number of other viral infections, including influenza virus, hepatitis C virus and rotavirus (37) , but the enrichment of VH3-33, apparent in all three patients, appears to be specific for COVID-19. In contrast, VH4-34 and VH3-23 were substantially underrepresented in SARS-CoV-2-specific sequences compared to the naive repertoire (8-fold and 4-fold decrease in frequency, respectively). While the usage of most VH genes was consistent between COVID-19 patients, particularly VH3-30-3 and VH4-39 showed considerable variance. Thus, upon SARS-CoV-2 infection the S protein recruits a subset of B cells from the naive repertoire enriched in specific VH segments and CDRH3 domains.

Subsequently, all HC and LC pairs were transiently expressed in HEK 293T cells and screened for binding by ELISA to SARS-CoV-2 S protein. 84 mAbs that showed potent binding were selected for small-scale expression in HEK 293F cells and purified. We obtained few S protein-reactive mAbs from COSCA3, possibly because the majority of B cells from this individual were IgM + . Surface plasmon resonance (SPR) assays showed binding of 77 mAbs to S protein with binding affinities in the nano-to picomolar range (Table S1 ). To gain insight in the immunodominance of the RBD as well as the ability to cross-react with SARS-CoV, we assessed the binding capacity of these mAbs to the prefusion S proteins and the RBDs of SARS-CoV-2 and SARS-CoV by ELISA. Of the 84 mAbs that were tested, 32 (38%) bound to the SARS-CoV-2 RBD (Fig. 4 , A and B) with 7 mAbs (22%) showing cross-binding to SARS-CoV RBD (Fig. S4A) . Interestingly, we also observed 33 mAbs (39%) that bound strongly to SARS-CoV-2 S but did not bind the RBD, of which 10 mAbs (30%) also bound to the S protein of SARS-CoV (Fig. 4, A and B) . Notably, some mAbs that bound very weakly to soluble SARS-CoV-2 S protein in ELISA showed strong binding to membrane-bound S protein, implying that their epitopes are presented poorly on the stabilized soluble S protein (Table S1 ).

All 84 mAbs were subsequently tested for their ability to block infection. 19 mAbs (23%) ACE2 binding, further supporting that blocking ACE2 binding is their mechanism of neutralization ( Fig. S4C) . The RBD-targeting mAb COVA2-17, however, did not show competition as strong as other RBD-targeting mAbs. This corroborates previous observations that the RBD encompasses multiple distinct antigenic sites of which some do not block ACE2 binding (23) . Interestingly, the non-RBD NAbs all bear substantially longer CDRH3s compared to RBD NAbs (Fig. S4D) , suggesting a convergent CDRH3-dependent contact between antibody and epitope.

A major concern with convalescent serum treatment is ADE. We observed a low level of concentration-dependent enhancement of infection (<2-fold) for a small number of mAbs, which could indicate a possible role of the antibodies in ADE (Fig. S4E) . Although, we did not observe ADE for the polyclonal sera, the observation that some mAbs have this property should induce caution when using poorly characterized convalescent plasma for therapy and supports the search for mAbs, which can be specifically selected for the desired properties of strong neutralization potency and absence of ADE.

To identify and characterize the antigenic sites on the S protein and their interrelationships we performed SPR-based cross-competition assays followed by clustering analysis. We note that competition clusters do not necessarily equal epitope clusters, but the analysis can provide clues on the relation of mAb epitopes. We identified 11 competition clusters of which nine contained more than one mAb while two contained only one mAb (clusters X and XI; Fig. 5 ).

All nine multiple-mAb clusters included mAbs from at least two of the three patients, emphasizing that these clusters represent common epitopes targeted by the human humoral immune response during SARS-CoV-2 infection. Three clusters included predominantly RBDbinding mAbs (clusters I, III, VII), with cluster I forming two subclusters. Four clusters (V, VI, XIII and IX) included predominantly mAbs that did not interact with RBD, and clusters II, IV, X and XI consisted exclusively of non-RBD mAbs. mAbs with diverse phenotypes (e.g. RBD and non-RBD binding mAbs) clustered together in multiple clusters, suggesting that these mAbs might target epitopes bridging the RBD and non-RBD sites or that they sterically interfere with each other's binding as opposed to binding to overlapping epitopes. While clusters II, V and VIII contained only mAbs incapable of neutralizing SARS-CoV-2, clusters I, III, IV, VI and VII included both non-NAbs and NAbs. Interestingly, cluster V was formed mostly by non-RBD targeting mAbs cross-binding to SARS-CoV. However, these mAbs were not able to neutralize either SARS-CoV-2 or SARS-CoV, suggesting that these mAbs target a conserved nonneutralizing epitope on the S protein. Finally, the two non-RBD mAbs COVA1-03 and COVA1-21 formed unique single-mAb competition clusters (cluster X and XI, respectively) and showed an unusual competition pattern, as binding of either mAb blocked binding by majority of the other mAbs. We hypothesize that these two mAbs allosterically interfere with mAb binding by causing conformational changes in the S protein that shield or impair the majority of other mAb epitopes. COVA1-21 also efficiently blocked virus infection, suggesting an alternative mechanism of neutralization than blocking ACE2 engagement. Overall, our data are consistent with the previous identification of multiple antigenic RBD sites for SARS-CoV-2 and additional non-RBD sites on the S protein as described for SARS-CoV and MERS-CoV (29, 38) . Here, our discovery of non-RBD-targeting mAbs provides additional depth to the definition of antibody epitopes on the SARS-CoV-2 S protein.

To visualize how selected NAbs bound to their respective epitopes, we generated Fab-SARS-CoV-2 S complexes that were imaged by single particle negative-stain electron microscopy (NS-EM; Fig. 5, B and C, and fig. S5 ). We obtained low-resolution reconstruction with six Fabs, including five RBD-binding Fabs. COVA1-12 is highly overlapping with the epitope of COVA2-39, while COVA2-04 approaches the RBD at a unique angle that is somewhat similar to the cross-binding SARS-CoV-specific mAb CR3022 (39) . The EM reconstructions confirmed the RBD as the target of these NAbs, but revealed a diversity in approach angles (Fig. 5B) .

Furthermore, while four RBD NAbs interacted with a stoichiometry of one Fab per trimer, consistent with one RBD being exposed in the "up state" and two in the less accessible "down state" (13, 40) , COVA2-15 bound with a stoichiometry of three per trimer (Fig. S5) . Strikingly, COVA2-15 is able to latch onto RBD domains in both the up or down state (Fig. 5D ). In either conformation the COVA2-15 epitope partially overlaps with the ACE2 binding site and therefore the mAb blocks receptor engagement. The higher stoichiometry of this mAb may explain its unusually strong neutralization potency. The epitopes of none of the five RBD Fabs overlapped with that of CR3022 which is unable to neutralize SARS-CoV-2 (39), although COVA2-04 does approach the RBD from a similar angle as CR3022. The sixth Fab for which we generated a 3D reconstruction was from the non-RBD mAb COVA1-22, placed in competition cluster IX. The EM demonstrated that this mAb bound to the N-terminal domain (NTD) of S1. COVA1-22 represents the first NTD-targeting NAb for SARS-CoV-2, although such NTD NAbs have been found for MERS-CoV (41).

In conclusion, convalescent COVID-19 patients showed strong anti-SARS-CoV-2 S protein specific B cell responses and developed memory and antibody producing B cells that may have participated in the control of infection and the establishment of humoral immunity. We The funders had no role in study design, data collection, data analysis, data interpretation or data reporting. Competing interests: Amsterdam UMC has filed a patent application concerning the SARS-CoV-2 mAbs described here. Data and materials availability: We will share reagents, materials and data presented in this study on request. Colored shading indicates the most potent mAbs from COSCA1-2. 

cluster I

cluster III

cluster III

cluster I

Side view Top view

An interactive web-based dashboard to track COVID-19 in real time

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis

Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Dynamics of Immune Activation in Viral Diseases

Controlled Trial of Ebola Virus Disease Therapeutics

Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea

Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study

Comparison of a Novel Human Rabies Monoclonal Antibody to Human Rabies Immunoglobulin for Postexposure Prophylaxis: A Phase 2/3, Randomized, Single-Blind, Noninferiority, Controlled Study

Palivizumab for respiratory syncytial virus prophylaxis

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Structure, Function, and Evolution of Coronavirus Spike Proteins

Structural basis of receptor recognition by SARS-CoV-2

A next-generation cleaved, soluble HIV-1 Env trimer

664 gp140, expresses multiple epitopes for broadly neutralizing but not nonneutralizing antibodies

Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits

Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses

Structure and function of respiratory syncytial virus surface glycoproteins

Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerging microbes & infections 9

A human monoclonal antibody blocking SARS-CoV-2 infection

Structural and functional analysis of a potent sarbecovirus neutralizing antibody. bioRxiv

Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor

Potent human neutralizing antibodies elicited by SARS-CoV-2 infection. bioRxiv

Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution

Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants

The potential of engineered antibodies for HIV-1 therapy and cure

Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19)

Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies

Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Infants Infected with Respiratory Syncytial Virus Generate Potent Neutralizing Antibodies that Lack Somatic Hypermutation

Commonality despite exceptional diversity in the baseline human antibody repertoire

In vitro evolution of an influenza broadly neutralizing antibody is modulated by hemagglutinin receptor specificity

Immunologic Basis for Long HCDR3s in Broadly Neutralizing Antibodies Against HIV-1

VH1-69 antiviral broadly neutralizing antibodies: genetics, structures, and relevance to rational vaccine design

Global profiling of SARS-CoV-2 specific IgG/ IgM responses of convalescents using a proteome microarray. medRxiv

A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2

Structural Definition of a Neutralization-Sensitive Epitope on the MERS-CoV S1-NTD

Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates

Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes

Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning

Enzymatic assembly of DNA molecules up to several hundred kilobases

An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability

Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes

SARS-CoV-2 specific antibody responses in COVID-19 patients. medRxiv

Leginon: a system for fully automated acquisition of 1000 electron micrographs a day

Appion: an integrated, database-driven pipeline to facilitate EM image processing

DoG Picker and TiltPicker: software tools to facilitate particle selection in single particle electron microscopy

RELION: implementation of a Bayesian approach to cryo-EM structure determination

UCSF Chimera--a visualization system for exploratory research and analysis